L'oreal

Societe L'oreal Sa

Loreal Sa

Centre International De Recherches Dermatologiques Galderma

Bruno Bernard

Maria Dalko

Jean-Baptiste Galey

Olivier Gaillard

Michel Philippe

Jean-François Michelet

Didier Semeria

Stephane Commo

Yann Mahe

Christophe Boulle

Bruno Charpentier

Patrick Pichaud

Geneviève Loussouarn

Catherine Gerst

Charles El Rawadi

Francedillaoise Jarrousse

Lionel Breton

Jean R Maignan

Olivier De Lacharriere

Dominique Bernard

Francis Pruche

Isabelle Castiel

Roger Rozot

Michelle Rathman Josserand

Nelly Billoni

Dominique Fagot

Claire Marionnet

Jean-Francedillaois Michelet

Françoise Bernerd

David Amar

Didier Saint Leger

José Halloy

Michele Vion

Albert Goldbeter

Peggy Sextius

Geneviéve Loussouarn

Mario Dalko

Stéphane Commo

The present invention concerns a method for evaluating the epidermal homeostasis of the skin of a subject, comprising differential analysis of the expression of a gene, preferably of two genes, selected from the group of genes consisting of KRT6B, KRT16, ESRRA, CBX3, MAP3K5, TRIO, PIK3CD, TCRB, PRRG2, ICP22BP, GPX3, GBA, BPGM, NID1, SMT3H2, LGALS2, DOC1, PRKCG, S100A8, S100A9, S100A2, S100A7, K15, SPRR1B and GSN in response to a physical or chemical challenge of the stratum corneum. It also concerns various methods for diagnosing the state of the epidermis of an individual and methods for detecting and screening products or procedures which can improve epidermal homeostasis. The invention also pertains to kits and arrays which can be used in these various methods and processes.

Molecular signature representative of dysfunctions in epidermal homeostasis

The present invention relates to a process for evaluating in vitro at least one active agent capable of preserving the functionality of epithelial stem cells, in particular of maintaining or stimulating the growth and/or the density and/or the renewal of a keratin material, consisting in determining the ability of the active agent(s) to mimic a hypoxic state in the keratin material, the active agent(s) being capable of increasing the expression of at least carbonic anhydrase IX as biological marker of hypoxia, in the keratin material treated with the active agent(s) compared with the keratin material not treated with the active agent(s). It also relates to the use of such a process.

Process for evaluating active agent(s) capable of preserving the functionality of epithelial stem cells

The invention relates to the use in a composition for caring for human hair or eyelashes of an effective amount of a pyridinedicarboxylic acid derivative of general formula (I) or of one of its salts, in which Rand Rrepresent, independently of one another, OH, OR', &#x2014;NH, &#x2014;NHR&#x2032; or &#x2014;NR&#x2032;R&#x2033;, and R&#x2032; and R&#x2033; represent, independently of one another, a saturated or unsaturated and linear or branched C-Calkyl radical or an aryl radical, this alkyl or aryl radical optionally being substituted by at least one OH, alkoxy, acyloxy, amino or alkylamino group, or R&#x2032; and R&#x2033; together represent a heterocycle, the composition being intended to induce and/or stimulate the growth of human keratinous fibers, such as the hair and eyelashes, and/or slow down their loss; the invention also relates to a cosmetic treatment intended to stimulate the growth of human keratinous fibers, such as the hair and eyelashes, and/or slow down their loss.

Administration of pyridinedicarboxylic acid compounds for stimulating or inducing the growth of human keratinous fibers and/or arresting their loss

An O-acyl product derived from glucose which may be obtained by partial or total esterification of glucose and of vitamin F, comprising a mixture of esters, for example, monoesters, of glucose and of at least one acid chosen from linoleic acid, oleic acid, palmitic acid and stearic acid, compositions, for example, cosmetic and pharmaceutical compositions, comprising this novel derivative, and their use for improving the condition of head hair and/or other hairs, and, for example, for reducing and/or impeding the loss of head hair and/or other hairs, and/or for inducing and/or stimulating hair growth, as well as a process for preparing O-acyl derivatives mainly in position 6 of glucose, comprising preparing a mixed anhydride by reacting a carboxylic acid with a trimethylacetyl halide, followed by reacting said mixed anhydride formed with glucose.

Derivative of glucose and vitamin F, compositions comprising it, uses and preparation process

At least one phytosphingosine salicylate derivative and at least one lysate of at least one microorganism of the genus. Composition, combination. Use, including cosmetic use for reinforcing the repair and regeneration capacity of an epithelium, especially an epidermis, in particular an aged epidermis.

Combination of a microorganism and a phytosphingosine derivative, composition, methods of use

Agents mimicking DOPAchrome tautomerase activity are administered, notably topically applied, to protect and/or regenerate the melanocytes of hair follicles, to promote the cyclic renewal of the follicular pigmentation unit, to prevent and/or limit and/or arrest the development of canities, and to maintain the natural pigmentation of gray or white head hair and/or body hair.

Administration of agents mimicking dopachrome tautomerase (TRP-2) activity for protecting hair follicle melanocytes

The present invention concerns the use of a polypeptide comprising a sequence having at least 90% identity with all or part of BNIPXL&#x3b2;, for cosmetic or therapeutic applications, in the treatment or prevention of premature canities in humans, said portion comprising at least 30 amino acids, as well as the use, for the same purpose, of a molecule comprising a RNAi sequence having at least 90% identity with all or part of the cDNA sequence of BNIPXL&#x3b2;, said part comprising at least 18 nucleotides. The invention also concerns methods for screening molecules modulating the expression of a gene coding for BNIPXL-beta and molecules modulating the activity of the BNIPXL-beta polypeptide, in order to identify an agent for use for cosmetic or therapeutic purposes in the field of pigmentation. The invention also encompasses various uses of molecules which may be identified by these methods.

Uses of BNIPXL-beta in premature canities

Derivative of glucose and of vitamin F, compositions comprising it, uses and preparation process

Administration of agents mimicking DOPAchrome tautomerase (TRP-2) activity for protecting hair follicle melanocytes

The invention relates to a cosmetic composition containing at least one 15-hydroxy-prostaglandin dehydrogenase inhibitor and cosmetically acceptable excipients. It also relates to a method of cosmetic treatment for promoting the growth and/or preventing or delaying the loss of hair, and the use of a 15-hydroxyprostaglandin dehydrogenase inhibitor for the preparation of a composition intended for controlling hair loss and/or for promoting hair regrowth.

Cosmetic composition, method of cosmetic treatment and preparation of a composition for promoting the growth and/or preventing or delaying the loss of hair

System for the simulation of the evolution of a region of the scalp of a subject over time, comprising a means of observation of the said hair region able to output digital observation data, a first digital data processing means capable of classifying elementary parts of the said region on the basis of the observation data, a second digital data processing means capable of simulating the evolution of the said hair region as a function of the data emanating from the first digital data processing means, and a means of displaying the data emanating from the second digital data processing means.

System and process for the analysis and predictive simulation of the temporal evolution of a hair region, and more particularly of the human scalp

The invention relates to the use, as active principle, in a physiologically acceptable medium, in a composition, of an effective amount of at least one compound of the indolecarboxylic family, this compound or these compositions being intended to treat disorders associated with overactivity of 5&agr;-reductase. These compounds or the compositions containing them are more particularly intended to treat androgen-dependent disorders such as, for example, seborrhoea and/or acne and/or hirsutism and/or androgenic alopecia. The invention also relates to novel compounds of the indolecarboxylic family and to compositions-containing them.

Compounds of the indolecarboxylic family and use thereof

Growing community of inventors

Neuilly sur Seine, France

Bruno Bernard